We are trying to stay away from the me too business strategy

We are trying to stay away from the ‘me too’ business strategy. Our growth strategy is divided into several verticals:interview-med

  1. Domestic Supply chain solution: WHO GDP certified domestic supply chain solution – today’s pharma
    logistics is outsourced to regular logistics companies with no knowledge about recalls, ADRs, or pharmacy vigilance. We plan to offer an end to end solution to manufacturer from the factory gate to the retail shop, all under WHO GDP compliant process. This has over USD 2 billion market in India itself.
  2. Domestic Comparator supplies: Any development process consumes comparators worth USD 18 – 20 Million. Domestic comparator market is estimated to be over 500 Million USD annually. We are working to create awareness that there are Indian companies too which can supply comparators or references drugs at cost effective prices.
  3. Domestic Orphan Drug supplies: This is a neglected therapy area in India and estimated to about USD 200 Million annually. We are one of the early starters in this area and plan to build a lead anc continue maintaining it.
  4. International Markets – Global Speciality Wholesale: Global Pharma market is estimated to be around 340 Billion of which 80 Billion is Wholesale Trade_ Again, we are among the first few or the only professionally run, organised global wholesaler operating from India supplying medicines to over 180 countries globally. We target to capture a minimur-of 10 per cent of this global pie in nex: five years.

Read the full interview here

NEWSLETTER SIGNUP

Join our mailing list and stay updated
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.